Phibro Animal Health Corporation (PAHC) - Net Assets
Based on the latest financial reports, Phibro Animal Health Corporation (PAHC) has net assets worth $361.83 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.45 Billion) and total liabilities ($1.08 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Phibro Animal Health Corporation asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $361.83 Million |
| % of Total Assets | 25.04% |
| Annual Growth Rate | 9.19% |
| 5-Year Change | 19.77% |
| 10-Year Change | 215.74% |
| Growth Volatility | 518.24 |
Phibro Animal Health Corporation - Net Assets Trend (2000–2025)
This chart illustrates how Phibro Animal Health Corporation's net assets have evolved over time, based on quarterly financial data. Also explore PAHC total asset value for the complete picture of this company's asset base.
Annual Net Assets for Phibro Animal Health Corporation (2000–2025)
The table below shows the annual net assets of Phibro Animal Health Corporation from 2000 to 2025. For live valuation and market cap data, see PAHC company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $285.68 Million | +11.32% |
| 2024-06-30 | $256.64 Million | -9.16% |
| 2023-06-30 | $282.51 Million | +7.65% |
| 2022-06-30 | $262.44 Million | +10.03% |
| 2021-06-30 | $238.53 Million | +26.74% |
| 2020-06-30 | $188.20 Million | -12.87% |
| 2019-06-30 | $216.01 Million | +16.79% |
| 2018-06-30 | $184.95 Million | +22.36% |
| 2017-06-30 | $151.16 Million | +67.06% |
| 2016-06-30 | $90.48 Million | +205.39% |
| 2015-06-30 | $29.63 Million | +95.58% |
| 2014-06-30 | $15.15 Million | +121.97% |
| 2013-06-30 | $-68.94 Million | +21.86% |
| 2012-06-30 | $-88.23 Million | -63.76% |
| 2009-06-30 | $-53.88 Million | -40.33% |
| 2008-06-30 | $-38.39 Million | +56.37% |
| 2007-06-30 | $-88.00 Million | -5.14% |
| 2006-06-30 | $-83.70 Million | -86.41% |
| 2005-06-30 | $-44.90 Million | +29.62% |
| 2004-06-30 | $-63.80 Million | +24.59% |
| 2003-06-30 | $-84.60 Million | -38.24% |
| 2002-06-30 | $-61.20 Million | -1900.00% |
| 2001-06-30 | $3.40 Million | -89.27% |
| 2000-06-30 | $31.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Phibro Animal Health Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 731.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $272.70 Million | 95.46% |
| Common Stock | $4.00K | 0.00% |
| Other Comprehensive Income | $-124.02 Million | -43.41% |
| Other Components | $137.00 Million | 47.95% |
| Total Equity | $285.68 Million | 100.00% |
Phibro Animal Health Corporation Competitors by Market Cap
The table below lists competitors of Phibro Animal Health Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NICE Information Service Co. Ltd
KQ:030190
|
$709.61 Million |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581
|
$709.87 Million |
|
Zhejiang Kanglongda Special
SHG:603665
|
$710.10 Million |
|
LSI Industries Inc
NASDAQ:LYTS
|
$710.16 Million |
|
Hello Group Inc
NASDAQ:MOMO
|
$709.59 Million |
|
Brookfield Real Assets Income
NYSE:RA
|
$709.47 Million |
|
Lotte Chilsung Beverage
KO:005300
|
$709.31 Million |
|
Jinzai Food Group Co Ltd
SHE:003000
|
$709.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Phibro Animal Health Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 256,641,000 to 285,682,000, a change of 29,041,000 (11.3%).
- Net income of 48,264,000 contributed positively to equity growth.
- Dividend payments of 19,449,000 reduced retained earnings.
- Other comprehensive income decreased equity by 491,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $48.26 Million | +16.89% |
| Dividends Paid | $19.45 Million | -6.81% |
| Other Comprehensive Income | $-491.00K | -0.17% |
| Other Changes | $717.00K | +0.25% |
| Total Change | $- | 11.32% |
Book Value vs Market Value Analysis
This analysis compares Phibro Animal Health Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 63.95x to 4.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-06-30 | $0.53 | $33.68 | x |
| 2001-06-30 | $0.06 | $33.68 | x |
| 2002-06-30 | $-1.02 | $33.68 | x |
| 2003-06-30 | $-1.41 | $33.68 | x |
| 2004-06-30 | $-1.06 | $33.68 | x |
| 2005-06-30 | $-0.75 | $33.68 | x |
| 2006-06-30 | $-1.40 | $33.68 | x |
| 2007-06-30 | $-2.27 | $33.68 | x |
| 2008-06-30 | $-0.99 | $33.68 | x |
| 2009-06-30 | $-1.39 | $33.68 | x |
| 2012-06-30 | $-2.89 | $33.68 | x |
| 2013-06-30 | $-2.26 | $33.68 | x |
| 2014-06-30 | $0.47 | $33.68 | x |
| 2015-06-30 | $0.74 | $33.68 | x |
| 2016-06-30 | $2.26 | $33.68 | x |
| 2017-06-30 | $3.78 | $33.68 | x |
| 2018-06-30 | $4.58 | $33.68 | x |
| 2019-06-30 | $5.33 | $33.68 | x |
| 2020-06-30 | $4.65 | $33.68 | x |
| 2021-06-30 | $5.89 | $33.68 | x |
| 2022-06-30 | $6.48 | $33.68 | x |
| 2023-06-30 | $6.97 | $33.68 | x |
| 2024-06-30 | $6.33 | $33.68 | x |
| 2025-06-30 | $7.02 | $33.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Phibro Animal Health Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.89%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.72%
- • Asset Turnover: 0.95x
- • Equity Multiplier: 4.76x
- Recent ROE (16.89%) is above the historical average (2.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 31.96% | 3.13% | 1.25x | 8.18x | $6.94 Million |
| 2001 | -438.24% | -4.66% | 0.97x | 97.06x | $-15.24 Million |
| 2002 | 0.00% | -15.76% | 1.11x | 0.00x | $-45.68 Million |
| 2003 | 0.00% | -5.21% | 1.23x | 0.00x | $-9.15 Million |
| 2004 | 0.00% | 3.64% | 1.47x | 0.00x | $19.28 Million |
| 2005 | 0.00% | -6.06% | 1.44x | 0.00x | $-17.61 Million |
| 2006 | 0.00% | -3.29% | 1.60x | 0.00x | $-4.72 Million |
| 2007 | 0.00% | -1.48% | 1.67x | 0.00x | $2.10 Million |
| 2008 | 0.00% | 0.43% | 1.57x | 0.00x | $6.04 Million |
| 2009 | 0.00% | -1.55% | 1.49x | 0.00x | $-2.91 Million |
| 2012 | 0.00% | 1.07% | 1.48x | 0.00x | $15.80 Million |
| 2013 | 0.00% | 3.81% | 1.38x | 0.00x | $31.78 Million |
| 2014 | -20.46% | -0.45% | 1.46x | 31.18x | $-4.61 Million |
| 2015 | 203.46% | 8.05% | 1.52x | 16.65x | $57.32 Million |
| 2016 | 91.40% | 11.00% | 1.23x | 6.75x | $73.65 Million |
| 2017 | 42.74% | 8.45% | 1.23x | 4.12x | $49.48 Million |
| 2018 | 35.09% | 7.91% | 1.22x | 3.63x | $46.40 Million |
| 2019 | 25.32% | 6.61% | 1.14x | 3.36x | $33.10 Million |
| 2020 | 17.83% | 4.19% | 1.02x | 4.17x | $14.73 Million |
| 2021 | 22.80% | 6.53% | 0.99x | 3.53x | $30.53 Million |
| 2022 | 18.74% | 5.22% | 1.01x | 3.55x | $22.93 Million |
| 2023 | 11.54% | 3.33% | 1.01x | 3.44x | $4.36 Million |
| 2024 | 0.94% | 0.24% | 1.04x | 3.83x | $-23.25 Million |
| 2025 | 16.89% | 3.72% | 0.95x | 4.76x | $19.70 Million |
Industry Comparison
This section compares Phibro Animal Health Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $175,886,725
- Average return on equity (ROE) among peers: -32.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Phibro Animal Health Corporation (PAHC) | $361.83 Million | 31.96% | 2.99x | $709.59 Million |
| Aurora Cannabis Inc (ACB) | $1.36 Million | -29.41% | 0.39x | $201.62 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $12.75 Million |
| Akebia Ther (AKBA) | $104.08 Million | -35.58% | 0.07x | $278.59 Million |
| Alkermes Plc (ALKS) | $162.85 Million | -41.79% | 0.31x | $5.83 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $305.26 Million | -47.41% | 0.09x | $1.52 Billion |
| Amphastar P (AMPH) | $448.72 Million | 0.31% | 0.41x | $829.39 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-175.94 Million | 0.00% | 0.00x | $4.08 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -174.05% | 9.57x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $210.85 Million | 14.59% | 0.12x | $196.52 Million |
| ANI Pharmaceuticals Inc (ANIP) | $358.74 Million | -11.88% | 1.15x | $1.80 Billion |
About Phibro Animal Health Corporation
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including po… Read more